Journal of Nanobiotechnology

CORRECTION

Open Access

Correction:Targeting SUMOylation with an injectable nanocomposite hydrogel to optimize radiofrequency ablation therapy for hepatocellular carcinoma

Junfeng Liu[1,2,3,4†], Xi Li[1,2,4*†], Jiawen Chen[1,2,3,4†], Jingpei Guo[1,2,3,4], Hui Guo[1,2,4], Xiaoting Zhang[1,2,3,4], Jinming Fan[1,2,3,4], Ke Zhang[1,2,3,4], Junjie Mao[1,2,4*] and Bin Zhou[1,2,3,4*]

Correction: Journal of Nanobiotechnology (2024) 22:338
https://doi.org/10.1186/s12951-024-02579-1

In this article the wrong figure appeared as Fig. 6: author corrections in the title of the graph in panel E and

†Junfeng Liu, Xi Li and Jiawen Chen have contributed equally to this work.

The original article can be found online at https://doi.org/10.1186/s12951-024-02579-1.

*Correspondence:
Xi Li
lixi57@mail.sysu.edu.cn
Junjie Mao
maojunj@mail.sysu.edu.cn
Bin Zhou
zhoub2@mail.sysu.edu.cn
[1] Center of Interventional Medicine, The Fifth Affiliated Hospital of Sun Yat-Sen University, Zhuhai 519000, Guangdong Province, China
[2] Institute of Interventional Radiology, Sun Yat-Sen University, Zhuhai 519000, Guangdong Province, China
[3] Center of Cerebrovascular Disease, The Fifth Affiliated Hospital of Sun Yat-Sen University, Zhuhai 519000, Guangdong Province, China
[4] Guangdong Provincial Engineering Research Center of Molecular Imaging, The Fifth Affiliated Hospital of Sun Yat-Sen University, Zhuhai 519000, Guangdong Province, China

in the image in panel H were not implemented due to a typesetting mistake. Figure 6 should have appeared as shown below.

Uncorrected figure





Fig. 6 Combining BT-NPs@PLEL with anti-PD-L1 treatment for inhibition in residual tumors after iRFA. **A** Schematic representation of treatment of residual tumor after iRFA in C57/BL6 mice. **B** Bioluminescence images of mice with residual tumors after iRFA after different treatments on days 0, 10, and 20 (n = 3). **C** Bioluminescence signals of mice in each group on day 0, 10, and 20 (n = 3). **D** Tumor volume of residual tumors after iRFA in different groups(n = 6). **E** The weight of residual tumors on day 21 after different treatments (n = 6). **F** Survival analysis of experimental mice in different groups (n = 6). **G** Representative Flow cytometry plots and proportions of CD8+ T cells on day 7 (n = 6). **H** Representative flow cytometry plots and proportions of Granzyme B+ cells on day 7 (n = 6). ns, not significant *$p < 0.05$, **$p < 0.01$, ***$p < 0.001$

Corrected figure

The original article has been corrected. The publisher apologises to the authors and readers for the inconvenience caused by this error.

Published: 2 August 2024